And (earlier) here's what we expect: an inline quarter, with pembrolizumab on pace to hit $6 billion in sales for the full year 2018.
Forbes has a reprint of a Trefis prediction piece, thus:
. . . .We expect Merck’s Oncology revenue to grow by more than 30% to north of $6.0 billion in 2018, primarily led by a ramp up in Keytruda sales. Merck EPS will likely be near $1.03 while revenue will be around $10.29 billion, according to analysts. . . .
In fact, Keytruda sales more than doubled to nearly $1.5 billion in the previous quarter. . . . The Keynote-189 results from earlier this year were encouraging for a combination of Keytruda with chemotherapy for nonsquamous first-line lung cancer. The drug’s peak sales are estimated to be as high as $10 billion, and it will likely continue to drive growth for Merck in the coming years. . . .
Looking at other segments, we expect Vaccines to see strong growth led by Gardasil, which saw an impressive 24% growth in the previous quarter.
Now you know -- and onward, to a West Coast status hearing on the migrants' children. The US government has admitted overnight that it "couldn't be bothered" to gather any details, for reuniting at least 40 children, when it took them away from their parents. These are ongoing crimes against humanity -- directly ordered by Donald J. Trump. He is -- in fact -- deplorable.
नमस्ते
No comments:
Post a Comment